No Data
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Express News | Aptevo Therapeutics - Favorable Early Safety, Efficacy, Tolerability,Durability of Remission Data Informed Co's Ongoing Rainier Phase 1B/2 Trial
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Aptevo Therapeutics And Alligator Bioscience's Bispecific Antibody ALG.APV-527 Meets Key Endpoints In Phase 1 Solid Tumor Trial; Shows Favorable Safety And Immune Activation With Stable Disease In Colon And Breast Cancer Patients
Aptevo Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.
10-Q: Q3 2024 Earnings Report
No Data
No Data
